1. Home
  2. MLYS vs ETJ Comparison

MLYS vs ETJ Comparison

Compare MLYS & ETJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$29.17

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo Eaton Vance Risk-Managed Diversified Equity Income Fund of Beneficial Interest

ETJ

Eaton Vance Risk-Managed Diversified Equity Income Fund of Beneficial Interest

HOLD

Current Price

$8.51

Market Cap

543.8M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
ETJ
Founded
2019
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
543.8M
IPO Year
2023
2007

Fundamental Metrics

Financial Performance
Metric
MLYS
ETJ
Price
$29.17
$8.51
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$48.67
N/A
AVG Volume (30 Days)
998.0K
152.6K
Earning Date
05-06-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
37.43
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.59
$7.88
52 Week High
$47.65
$9.12

Technical Indicators

Market Signals
Indicator
MLYS
ETJ
Relative Strength Index (RSI) 56.93 56.25
Support Level $26.85 $8.30
Resistance Level $31.19 $9.04
Average True Range (ATR) 1.58 0.09
MACD 0.07 0.02
Stochastic Oscillator 65.43 74.07

Price Performance

Historical Comparison
MLYS
ETJ

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About ETJ Eaton Vance Risk-Managed Diversified Equity Income Fund of Beneficial Interest

Eaton Vance Risk-Managed Diversified Equity Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation. The group invests in various sectors such as financials, healthcare, consumer discretionary, consumer staples, industrials, energy, utilities, telecommunication services, and materials. Under normal market conditions, the Fund's investment program consists of majorly owning a diversified portfolio of common stocks and employing a variety of options strategies.

Share on Social Networks: